TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04010643

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online cognitive behavioural therapy
Description: oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online cognitive behavioural therapy
Description: oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online neurocognitive remediation therapy
Description: NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
Study: NCT01419717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection every 4 weeks (Q4W)
Study: NCT02857283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
Study: NCT00430521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 2
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 2
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 2
Description: 2 or 3 doses, intramuscular injection, at different time points.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 2
Description: 2 or 3 doses, intramuscular injection, at different time points.
Study: NCT01560546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: 50 mg/dose/day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo on the skin for 24 weeks
Study: NCT01423617

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zenoctil
Description: 3 tablets 2 times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets 2 times daily
Study: NCT02704728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thetanix
Description: Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
Study: NCT02232672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choline PET/CT and MeAIB PET/CT
Description: Choline PET/CT and MeAIB PET/CT
Study: NCT02370849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
Study: NCT00108628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal
Description: IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Nightmare Management
Description: This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
Study: NCT03527680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Description: daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: daily one capsule of placebo
Study: NCT03068845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon angioplasty (DEBA)
Description: DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balloon Angioplasty (CBA)
Description: CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin.
Study: NCT02339415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban 30mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study: NCT03259191

Intervention type: PROCEDURE
Group type: OTHER
Intervention: anti-reflux mucosectomy
Description: Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: anti-reflux mucosectomy
Description: Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
Study: NCT03856606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting without exercise
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with interval exercise
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
Study: NCT02711033

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted total gastrectomy
Description: When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open total gastrectomy
Description: When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
Study: NCT00945334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: 500 mg po bid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: 500 mg po bid for 14 days
Study: NCT02041793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cystogastrostomy
Description: Patients undergo drainage of pseudocyst by laparoscopic technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cystogastrostomy
Description: Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
Study: NCT02370849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
Study: NCT01009801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin-eluting beads
Description: Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin-eluting beads
Description: Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Study: NCT03184298

Intervention type: OTHER
Group type: OTHER
Intervention: Surveys
Description: The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.

Intervention type: OTHER
Group type: OTHER
Intervention: Interviews
Description: These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.

Intervention type: OTHER
Group type: OTHER
Intervention: Group Discussions
Description: The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
Study: NCT03176940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
Study: NCT00006708

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: 5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study: NCT03611933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: position change applied at different times
Description: Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
Study: NCT01165021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Administered Intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally.
Study: NCT04086563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation
Description: look at a clip of a hand doing neurodynamic exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation
Description: look at a clip of a hand doing neurodynamic exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action observation
Description: look at a clip of a hand doing neurodynamic exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic exercises
Description: active movement of the dominant hand. Do neurodynamic exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic exercises
Description: active movement of the dominant hand. Do neurodynamic exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodynamic exercises
Description: active movement of the dominant hand. Do neurodynamic exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: Execute a short strength training for the dominant hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: Execute a short strength training for the dominant hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: Execute a short strength training for the dominant hand
Study: NCT02049255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroprocaine
Description: The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marcaine
Description: The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia
Study: NCT01810198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT
Description: Perform a non-invasive Cardiac CT Angiogram

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Coronary Angiography
Description: Patient undergoes Invasive Coronary Angiography
Study: NCT00579124

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACs
Description: T and B Cell depletion

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACs
Description: T and B Cell depletion
Study: NCT00945334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for 14 days tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550 mg po tid
Study: NCT02129309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm plethysmography
Description: Dose response study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemodynamic studies
Description: Dose response study
Study: NCT00808509

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg every other week via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: At least 10 mg/week administered orally or subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: At least 10 mg/week administered orally or subcutaneously
Study: NCT04666688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-200
Description: monoclonal antibody (mAb), targeting galectin-9 protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-200
Description: monoclonal antibody (mAb), targeting galectin-9 protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-200
Description: monoclonal antibody (mAb), targeting galectin-9 protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/nab-paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/nab-paclitaxel
Description: chemotherapy
Study: NCT04397289

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Heparin and Rivaroxaban
Description: Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin and Rivaroxaban
Description: Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin and Rivaroxaban
Description: Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
Study: NCT04347525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CaCBT based guided self help using Khushi aur Khatoon Manual
Description: CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
Study: NCT03355352

Intervention type: DRUG
Intervention: Sufentanil
Description: Sufentail sublingual 15ug nanopills
Study: NCT01992016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 1000mg given orally twice daily for 1 day (2 doses).